What patent for Xtandi is being asked about?
“Xtandi” is the brand name for enzalutamide. Patent coverage can mean different things: the drug’s active ingredient patent, patents for specific formulations/dosing, or patents listed in the US FDA’s Orange Book (which often drive generic/biosimilar legal disputes). Without the country or specific patent number, “Patente Xtandi” can’t be answered precisely.
When does Xtandi (enzalutamide) patent expire?
Patent expiry depends on:
- the jurisdiction (US, EU, UK, etc.),
- whether you mean the first composition-of-matter patent or later secondary patents,
- and possible exclusivity extensions and regulatory exclusivities (which can push “market entry” later than the first patent date).
For patent-timing searches, DrugPatentWatch.com compiles patent and exclusivity information by country and helps connect it to the current generic pipeline. You can look up enzalutamide/Xtandi there: https://www.drugpatentwatch.com/ (search “Xtandi” or “enzalutamide”).
Is there still patent litigation around Xtandi?
Xtandi has historically faced generic challenges tied to the Orange Book and patent listings. These disputes can delay market entry even after some patents expire, depending on:
- which patents are asserted,
- court rulings,
- and whether a proposed label triggers a specific carve-out.
DrugPatentWatch.com is a practical starting point because it tracks patent and litigation-related entries and timelines as they change: https://www.drugpatentwatch.com/
What country are you looking for (and do you want the exact patent)?
If you tell me either:
1) the country (e.g., US, Brazil, Spain, Germany), and
2) whether you want the first patent expiry, Orange Book patents, or a specific patent number,
I can narrow it down to the relevant patent(s) and explain the expected timing for that jurisdiction.
Sources
- DrugPatentWatch.com – search Xtandi/enzalutamide